Abstract
Although external-beam radiation therapy (EBRT) has been an effective treatment modality in patients with bilateral advanced retinoblastoma, it significantly increases the risk of second malignancies and facial deformities. This study aimed to evaluate the efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) for treatment, instead of EBRT, in children with bilateral advanced retinoblastoma. Fourteen patients with bilateral retinoblastoma received chemotherapy, and local therapy was provided whenever possible. When at least one functional eye could not be saved by chemoreduction and local therapy, tandem HDCT/ASCR was provided to avoid EBRT. As a result, nine patients received tandem HDCT/ASCR. The toxicities were tolerable and there was no TRM. All nine patients who received tandem HDCT/ASCR had at least one functional eye without EBRT, and in two patients, both eyes were saved. No second malignancy has developed to date. HDCT/ASCR might be an effective treatment for bilateral advanced retinoblastoma, especially in cases in which at least one functional eye could not be preserved with chemoreduction and local therapy alone, and where EBRT was unavoidable. Long-term follow-up and further studies are needed to evaluate the efficacy and toxicity of HDCT/ASCR as an alternative treatment to EBRT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Roarty JD, McLean IW, Zimmerman LE . Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 1988; 95: 1583–1587.
Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005; 23: 2272–2279.
Shields CL, Honavar SG, Meadows AT, Shields JA, Demirici H, Singh A et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002; 133: 657–664.
Friedman DL, Himelstein B, Shields CL, Shields JA, Needle M, Miller D et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000; 18: 12–17.
Beck MN, Balmer A, Dessing C, Pica A, Munier F . First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 2000; 18: 2881–2887.
Lee V, Hungerford JL, Bunce C, Ahmed F, Kingston JE, Plowman PN . Globe conserving treatment of the only eye in bilateral retinoblastoma. Br J Ophthalmol 2003; 87: 1374–1380.
George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006; 24: 2891–2896.
Sung KW, Yoo KH, Cho EJ, Koo HH, Lim do H, Shin HJ et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 2007; 48: 408–415.
Sung KW, Lee SH, Yoo KH, Jung HL, Cho EJ, Koo HH et al. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant 2007; 40: 37–45.
Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 2002; 20: 2284–2292.
Shields JA, Shields CL . Atlas of Intraocular Tumors. Lippincott Williams & Wilkins: Philadelphia, PA, 1999, pp 207–232.
Shields CL, Shields JA . Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus 1999; 36: 8–18.
Namouni F, Doz F, Tanguy ML, Quintana E, Michon J, Pacquement H et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer 1997; 33: 2368–2375.
Dunkel IJ, Aledo A, Kernan NA, Kushner B, Bayer L, Gollamudi SV et al. Successful treatment of metastatic retinoblastoma. Cancer 2000; 89: 2117–2221.
Kremens B, Wieland R, Reinhard H, Neubert D, Beck JD, Klingebiel T et al. High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant 2003; 31: 281–284.
Matsubara H, Makimoto A, Higa T, Kawamoto H, Skiyama S, Hosono A et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant 2005; 35: 763–766.
Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA . Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors. Trans Am Ophthalmol Soc 2004; 102: 35–45.
Gündüz K, Günalp I, Yalçinda∂ N, Unal E, Taçyildiz N, Erden E et al. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Ophthalmology 2004; 111: 1917–1924.
Abramson DH, Beaverson KL, Chang ST, Dunkel IJ, McCormick B . Outcome following initial external beam radiotherapy in patients with Reese–Ellsworth group Vb retinoblastoma. Arch Ophthalmol 2004; 122: 1316–1323.
Bechrakis NE, Bornfeld N, Schueler A, Coupland SE, Henze G, Foerster MH . Clinicopathologic features of retinoblastoma after primary chemoreduction. Arch Ophthalmol 1998; 116: 887–893.
Demirci H, Eagle Jr RC, Shields CL, Shields JA . Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Arch Ophthalmol 2003; 121: 1125–1131.
Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106: 1473–1478.
Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, Hellmann A, Kachel L, Holowiecki J et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 2004; 15: 1222–1230.
Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3440–3446.
Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998; 16: 3386–3391.
Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003; 21: 4083–4091.
Acknowledgements
We thank the residents and nurses who cared for the patients, and without whom this study would not have been possible.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Lee, S., Yoo, K., Sung, K. et al. Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma. Bone Marrow Transplant 42, 385–391 (2008). https://doi.org/10.1038/bmt.2008.181
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.181